PMID- 34811924
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220715
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 18
IP  - 4
DP  - 2022 Aug
TI  - Real-world multicenter study of the safety and efficacy of netupitant plus 
      palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and 
      vomiting among Malaysian patients receiving moderately or highly emetogenic 
      chemotherapy.
PG  - 419-427
LID - 10.1111/ajco.13667 [doi]
AB  - AIM: A large proportion of cancer patients are at high risk for 
      chemotherapy-induced nausea and vomiting (CINV), but the choice of anti-emetics 
      for CINV in Malaysia is limited. METHODS: This was a real-world study of a 
      fixed-dose combination of netupitant and palonosetron (NEPA) to inhibit CINV in 
      adult patients receiving moderately (MEC) or highly emetogenic chemotherapy (HEC) 
      for solid/hematological malignancies at eight Malaysian centers. Each HEC/MEC 
      cycle received one dose of NEPA + dexamethasone for CINV prevention. Complete 
      response (no emesis, no rescue medication) (CR), no more than mild nausea 
      (severity score </= 2.5), and complete control (CR) (no more than mild nausea) 
      during the acute (0-24 h), delayed (25-120 h), and overall (0-120 h) phases 
      post-chemotherapy were measured. Treatment-related adverse events (AEs) were 
      recorded. RESULTS: During March 2016-April 2018 (NMRR-17-3286-38282), NEPA + 
      dexamethasone was administered to 54 patients (77.8% solid, 22.2% hematological 
      malignancies). Note that 59.3% received HEC, while 40.7% received MEC regimen. 
      During the overall phase of the first cycle, the majority had CR (77.8%), no more 
      than mild nausea (74.1%), and complete control (61.1%). Seventeen patients 
      received two consecutive cycles at any point of chemotherapy cycles. During the 
      overall phases across two consecutive cycles, all patients achieved CR, and the 
      majority reported no more than mild nausea and complete control. No grades 3-4 
      AEs were reported. CONCLUSIONS: NEPA had sustained efficacy and tolerability at 
      first administration and across two cycles of MEC/HEC for CINV prevention.
CI  - (c) 2021 John Wiley & Sons Australia, Ltd.
FAU - Md Yusof, Mastura
AU  - Md Yusof M
AUID- ORCID: 0000-0001-8634-0468
AD  - Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
FAU - Abdullah, Matin Mellor
AU  - Abdullah MM
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
FAU - Yap, Beng Khiong
AU  - Yap BK
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
FAU - Ng, Soo Chin
AU  - Ng SC
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
FAU - Low, John Seng Hooi
AU  - Low JSH
AD  - Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
FAU - Lam, Kai Seng
AU  - Lam KS
AD  - Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
FAU - Ahmad Badruddin, Radzi Bin Ahmad
AU  - Ahmad Badruddin RBA
AD  - Dr A. Radzi's Integrated Oncology Clinic and Daycare Centre, Johor Bahru, 
      Malaysia.
FAU - Lai, Christina Nye Bing
AU  - Lai CNB
AD  - Sunway Medical Centre, Petaling Jaya, Selangor, Malaysia.
FAU - Lau, Kah Liew
AU  - Lau KL
AD  - Borneo Medical Centre, Kuching, Sarawak, Malaysia.
FAU - Chong, Kwang Jeat
AU  - Chong KJ
AD  - Mahkota Medical Centre, Melaka, Malaysia.
FAU - Nonis, Joel Gabriel
AU  - Nonis JG
AD  - Pantai Hospital Ayer Keroh, Melaka, Malaysia.
FAU - Ahmad Annuar, Muhammad Azrif
AU  - Ahmad Annuar MA
AD  - Prince Court Medical Centre, Kuala Lumpur, Malaysia.
FAU - Abdul Rahman, Mohd Haris Fadzillah Bin
AU  - Abdul Rahman MHFB
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211123
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzeneacetamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyridines)
RN  - 0 (Quinuclidines)
RN  - 5D06587D6R (Palonosetron)
RN  - 7732P08TIR (netupitant)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - *Antiemetics/therapeutic use
MH  - *Antineoplastic Agents/adverse effects
MH  - Benzeneacetamides
MH  - Dexamethasone
MH  - *Hematologic Neoplasms/drug therapy
MH  - Humans
MH  - Nausea/chemically induced/prevention & control
MH  - Palonosetron/adverse effects
MH  - Piperazines
MH  - Pyridines
MH  - Quinuclidines/adverse effects
MH  - Vomiting/chemically induced/prevention & control
OTO - NOTNLM
OT  - anti-emetics
OT  - hematological malignancies
OT  - nausea
OT  - solid tumor
OT  - vomiting
EDAT- 2021/11/24 06:00
MHDA- 2022/07/16 06:00
CRDT- 2021/11/23 06:56
PHST- 2021/07/16 00:00 [received]
PHST- 2021/08/17 00:00 [accepted]
PHST- 2021/11/24 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2021/11/23 06:56 [entrez]
AID - 10.1111/ajco.13667 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2022 Aug;18(4):419-427. doi: 10.1111/ajco.13667. Epub 2021 
      Nov 23.